Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleftheria Makri

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Personalized Medicine|July 27, 2022
Combination Therapies for Nonalcoholic Fatty Liver DiseaseEvangelia S Makri, Eleftheria Makri, Stergios A Polyzos
Annals of Gastroenterology|May 23, 2024
Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver diseaseEvangelia S Makri, Eleftheria Makri, Antonis Goulas, et al.
BMC Bioinformatics|December 22, 2018
Towards practical privacy-preserving genome-wide association studyCharlotte Bonte, Eleftheria Makri, Amin Ardeshirdavani, et al.
Journal of Clinical and Experimental Hepatology|March 4, 2024
Circulating Ferritin in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysisEleftheria Makri, Myrsini Orfanidou, Evangelia S Makri, et al.
International Journal of Molecular Sciences|October 16, 2025
Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse ModelEvangelia S Makri, Thomai Mouskeftara, Helen Gika, et al.
Endocrine|March 20, 2024
Partial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver diseaseEvangelia S Makri, Konstantinos Xanthopoulos, Panagiotis Mavrommatis Parasidis, et al.
Hormones (Athens, Greece)|December 19, 2024
Limited preventive effects of empagliflozin against metabolic dysfunction-associated steatotic liver disease in a mouse model of fast food dietEvangelia S Makri, Konstantinos Xanthopoulos, Spyros Pettas, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Personalized Medicine|July 27, 2022
Combination Therapies for Nonalcoholic Fatty Liver DiseaseEvangelia S Makri, Eleftheria Makri, Stergios A Polyzos
Annals of Gastroenterology|May 23, 2024
Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver diseaseEvangelia S Makri, Eleftheria Makri, Antonis Goulas, et al.
BMC Bioinformatics|December 22, 2018
Towards practical privacy-preserving genome-wide association studyCharlotte Bonte, Eleftheria Makri, Amin Ardeshirdavani, et al.
Journal of Clinical and Experimental Hepatology|March 4, 2024
Circulating Ferritin in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysisEleftheria Makri, Myrsini Orfanidou, Evangelia S Makri, et al.
International Journal of Molecular Sciences|October 16, 2025
Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse ModelEvangelia S Makri, Thomai Mouskeftara, Helen Gika, et al.
Endocrine|March 20, 2024
Partial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver diseaseEvangelia S Makri, Konstantinos Xanthopoulos, Panagiotis Mavrommatis Parasidis, et al.
Hormones (Athens, Greece)|December 19, 2024
Limited preventive effects of empagliflozin against metabolic dysfunction-associated steatotic liver disease in a mouse model of fast food dietEvangelia S Makri, Konstantinos Xanthopoulos, Spyros Pettas, et al.
Pageof 1